Aslı KORUR, Çiğdem GEREKLİOĞLU, Mahmut YERAL, Mutlu KASAR, Hakan ÖZDOĞU, İlknur KOZANOĞLU, Can BOĞA, Nurhilal BÜYÜKKURT, Pelin KARACAOĞLU, Süheyl ASMA, Soner SOLMAZ

Red blood cell alloimmunization in patients with sickle cell disease in Turkey: a single centerretrospective cohort study

Amaç: Orak hücre hastalığının sık görüldüğü bölgemizde eritrosit alloimmmünizasyon sıklığını ve ilişkili durumları araştırmayı amaçladık. Gereç ve Yöntem: bu çalışma tek merkezli, zamansal kesitli ve geriye dönük kohort çalşıması olarak planlanmıştır. Toplamda 216 orak hücre hastalığı [Hemoglobin (Hb) SS, Hb S-? talasemi, Hb S-? talasemi] tanısı olan hasta çalışmaya dahil edilmiştir. Hastalar transfüzyon miktarına gore iki gruba ayrılmıştır. Yılda 6'dan daha az transfüzyon alan ya da eritroferez öyküsü olmayan hastalar Grup 1'e, yılda 6 ve daha fazla basit transfüzyon alan ya da eritroferez işlemine alınan hastalar Grup 2'ye dahil edilmiştir. Bulgular: Çalışmamıza 216 hasta dahil edilmiştir. Transfüzyon tedavisi alan toplam 216 hastanın 67 (%31.0)'sinde, Grup 1'deki 56 hastanın 17'sinde (%30.4), Grup 2'deki 160 hastanın 50'sinde (%31.3) tespit edilmiştir. Hastalar alloimmünizasyon gelişimi açısından analiz edildiğinde, çalışmamız ne orak hücre komplikasyonlarının alloimmünizasyon gelişimi için ne de alloimmünizasyonun ölüm için bir risk faktörü olmadığını göstermiştir. Sonuç: alloimmünizasyon sıklığı, tecrübeli merkezler dışında yapılan transfüzyonlarda alloimmünizasyonu önleyici politikalara yeteri kadar uyulmadığı konusunda fikir vermektedir. Bu nedenle orak hücre anemili hastalarda alloimmünizasyon, ayrıntılı eritrosit antijen tanımlama işlemi yapılarak azaltılabilir veya önlenebilir

Türkiye'deorak hücre hastalığına sahip hastalarda eritrosit alloimmünizasyonu: tek merkez geriye dönük kohort çalışması

Purpose: We aimed to investigate erythrocyte alloimmunization frequency and related factors in our region where SCD is common. Material and Methods: This study was planned as a single center, cross-sectional and retrospective cohort study. A total of 216 patients who had been followed up due to SCD [Hemoglobin (Hb) SS, Hb S-? thalassemia, Hb S-? thalassemia] were included in this study. Patients were divided to two groups according to amount of transfusion. The patients who had received less than 6 transfusions per year and who did not have the history of erythropheresis were allocated to Group 1, and the patients who had received 6 or more simple transfusion per year or who had undergone erythrocyte exchange were allocated to Group 2. Results: Of 216 SCD patients included in the study. Alloimmunization was detected in 67 (31.0%) out of 216 patients who underwent transfusion, and in 17 (30.4%) out of 56 patients in Group 1 and in 50 (31.3%) out of 160 patients in Group 2. When the patients were analyzed according to alloimmunization development, our study revealed that neither SCD complications are a risk factor for alloimmunization nor alloimmunization increases mortality rates. Conclusion: High alloimmunization frequency found in our study suggests the insufficient adherence of alloimmunization-prevention policies in RBC transfusions performed except experienced institutions. Therefore alloimmunization may be reduced or prevented through performing extended red cell typing among SCD patients

PDF

___

Desai PC, Deal AM, Pfaff ER, Qaqish B, Hebden LM, Park YA et al. Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease. Am J Hematol. 2015;90:691-5.
Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120:528-37.
Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062-71.
Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion. 2015;55:1378-87. Ashley-Koch AE.
Kangiwa U, Ibegbulam O, Ocheni S, Madu A, Mohammed N. Pattern and prevelence of alloimmunization in multiply transfused patients with sickle cell disease in Nigeria. Biomark Res. 2015;3:26.:
Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010;50:20-5.
Denbow CE, Chung EE, Serjeant GR. Pulmonary artery pressure and the acute chest syndrome in homozygous sickle cell disease. Br Heart J. 1993;69:536-8.
Guler E, Garipardic M, Dalkiran T, Davutoglu M. Premarital screening test results for ?-thalassemia and sickle cell anemia trait in east Mediterranean region of Turkey. Pediatr Hematol Oncol. 2010;27:608-13.
Asma S, Kozanoglu I, Tarım E, Sarıturk C, Gereklioglu C, Akdeniz A et al. Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy. Transfusion. 2015;55:36-44.
Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2013;2013:439-46.
Ugwu NI, Awodu OA, Bazuaye GN, Okoye AE. Red cell alloimmunization in multi-transfused patients with sickle cell anemia in Benin City, Nigeria. Niger J ClinPract. 2015;18:522-6.
Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, Dampier CD, Roseff SD. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013;53:704-9.
Elenga N, Niel L. Alloimmunization in patients with sickle cell disease in French Guiana. J Blood Transfus. 2015;2015:812934.
Aly R, El-sharnoby MR, Hagag AA. Frequency of red cell alloimmunization in patients with sickle cell anemia in an Egyptian referral hospital. Transfus Apher Sci. 2012;47:253-7.
Ameen R, Al Shemmari S, Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion. 2009;49:1649-54.